Compare
Dare Bioscience, Inc. vs 60 Degrees Pharmaceuticals, Inc. vs China SXT Pharmaceuticals, Inc. vs Longeveron Inc.
| Latest fiscal year | Dare Bioscience, Inc. DARE | 60 Degrees Pharmaceuticals, Inc. SXTP | China SXT Pharmaceuticals, Inc. SXTC | Longeveron Inc. LGVN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-03-31 | 2025-12-31 |
| Revenue | $1.03M | $1.01M | $1.14M | $1.20M |
| Revenue growth (YoY) | n/m | +65.5% | -34.6% | -49.9% |
| Gross margin | 71.3% (computed) | 22.3% | 21.9% | 67.0% |
| Operating margin | n/m | -771.6% | -625.9% | n/m |
| Net margin | n/m | -732.5% | -545.2% | n/m |
| Net income | -$13.40M | -$7.37M | -$6.21M | -$22.70M |
| EPS (Diluted) | -$1.20 | -$11.73 | -$9.13 | -$1.29 |
| Operating cash flow | -$9.90M | -$6.85M | -$4.02M | -$18.64M |
| Free cash flow | -$10.29M | -$6.99M | n/a | -$18.89M |
| Cash & equivalents | $24.71M | $1.51M | $28.18M | $4.66M |
| Total assets | $32.47M | $5.37M | $34.75M | $10.26M |
| Total liabilities | $29.63M | $1.99M | $5.05M | $4.59M |
| Shareholders' equity | $2.84M | $3.46M | $29.71M | $5.67M |
| Return on year-end equity | -471.4% | -212.7% | -20.9% | -400.1% |
| Shares outstanding | 14.50M | 1.16M | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Dare Bioscience, Inc. | 60 Degrees Pharmaceuticals, Inc. | China SXT Pharmaceuticals, Inc. | Longeveron Inc. |
|---|---|---|---|---|
| Latest | $1.03M Ended 2025-12-31 | $1.01M Ended 2025-12-31 | $1.14M Ended 2026-03-31 | $1.20M Ended 2025-12-31 |
| 1 year earlier | $9.8K Ended 2024-12-31 | $607.6K Ended 2024-12-31 | $1.74M Ended 2025-03-31 | $2.39M Ended 2024-12-31 |
| 2 years earlier | $2.81M Ended 2023-12-31 | $253.6K Ended 2023-12-31 | $1.93M Ended 2024-03-31 | $709.0K Ended 2023-12-31 |
| 3 years earlier | $10.00M Ended 2022-12-31 | $223.2K Ended 2022-12-31 | $1.97M Ended 2023-03-31 | $1.22M Ended 2022-12-31 |
| 4 years earlier | $0 Ended 2021-12-31 | n/a | $2.60M Ended 2022-03-31 | $1.31M Ended 2021-12-31 |